Tags

Type your tag names separated by a space and hit enter

Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications.
Nephrology (Carlton). 2011 Mar; 16(3):261-8.N

Abstract

Fibroblast growth factor 23 (FGF-23) is a recently discovered regulator of phosphate and mineral metabolism. Its main physiological function is the enhancement of renal phosphate excretion. FGF-23 levels are inversely related to renal function and in patients with chronic kidney disease (CKD) elevation in FGF-23 precedes the rise of serum phosphate. Studies have demonstrated an important role for FGF-23 in the development of secondary hyperparathyroidism through an effect on parathyroid hormone and calcitriol. In cross-sectional studies FGF-23 has been associated with surrogate markers of cardiovascular disease such as endothelial dysfunction and arterial stiffness. FGF-23 has also been associated with both progression of CKD and mortality in dialysis patients. The discovery of FGF-23 has provided a profound new insight into bone and mineral metabolism, and it may become an important biomarker and therapeutic target in CKD.

Authors+Show Affiliations

Department of Nephrology, Monash Medical Centre, Monash University, Clayton, Victoria, Australia. Matthew.Damasiewicz@monash.eduNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

21265930

Citation

Damasiewicz, Matthew J., et al. "Fibroblast Growth Factor 23 in Chronic Kidney Disease: New Insights and Clinical Implications." Nephrology (Carlton, Vic.), vol. 16, no. 3, 2011, pp. 261-8.
Damasiewicz MJ, Toussaint ND, Polkinghorne KR. Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications. Nephrology (Carlton). 2011;16(3):261-8.
Damasiewicz, M. J., Toussaint, N. D., & Polkinghorne, K. R. (2011). Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications. Nephrology (Carlton, Vic.), 16(3), 261-8. https://doi.org/10.1111/j.1440-1797.2011.01443.x
Damasiewicz MJ, Toussaint ND, Polkinghorne KR. Fibroblast Growth Factor 23 in Chronic Kidney Disease: New Insights and Clinical Implications. Nephrology (Carlton). 2011;16(3):261-8. PubMed PMID: 21265930.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications. AU - Damasiewicz,Matthew J, AU - Toussaint,Nigel D, AU - Polkinghorne,Kevan R, PY - 2011/1/27/entrez PY - 2011/1/27/pubmed PY - 2011/6/15/medline SP - 261 EP - 8 JF - Nephrology (Carlton, Vic.) JO - Nephrology (Carlton) VL - 16 IS - 3 N2 - Fibroblast growth factor 23 (FGF-23) is a recently discovered regulator of phosphate and mineral metabolism. Its main physiological function is the enhancement of renal phosphate excretion. FGF-23 levels are inversely related to renal function and in patients with chronic kidney disease (CKD) elevation in FGF-23 precedes the rise of serum phosphate. Studies have demonstrated an important role for FGF-23 in the development of secondary hyperparathyroidism through an effect on parathyroid hormone and calcitriol. In cross-sectional studies FGF-23 has been associated with surrogate markers of cardiovascular disease such as endothelial dysfunction and arterial stiffness. FGF-23 has also been associated with both progression of CKD and mortality in dialysis patients. The discovery of FGF-23 has provided a profound new insight into bone and mineral metabolism, and it may become an important biomarker and therapeutic target in CKD. SN - 1440-1797 UR - https://www.unboundmedicine.com/medline/citation/21265930/Fibroblast_growth_factor_23_in_chronic_kidney_disease:_New_insights_and_clinical_implications_ L2 - https://doi.org/10.1111/j.1440-1797.2011.01443.x DB - PRIME DP - Unbound Medicine ER -